Total Revenue
McKesson Total Revenue decreased by 9.3% to $96.30B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.0%, from $90.82B to $96.30B. Over 4 years (FY 2022 to FY 2026), Total Revenue shows an upward trend with a 11.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates market expansion or higher demand, while a decrease may signal market saturation or competitive pressure.
Detailed definition
Total revenue represents the gross inflow of economic benefits arising from the ordinary operating activities of the com...
Peer comparison
Standard across all public companies; peers in the medical device and diagnostics sector typically show steady growth correlated with product adoption.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $62.67B | $66.58B | $68.61B | $66.10B | $67.15B | $70.16B | $70.49B | $68.91B | $74.48B | $77.22B | $80.90B | $76.36B | $79.28B | $93.65B | $95.29B | $90.82B | $97.83B | $103.15B | $106.16B | $96.30B |
| QoQ Change | — | +6.2% | +3.1% | -3.7% | +1.6% | +4.5% | +0.5% | -2.2% | +8.1% | +3.7% | +4.8% | -5.6% | +3.8% | +18.1% | +1.8% | -4.7% | +7.7% | +5.4% | +2.9% | -9.3% |
| YoY Change | — | — | — | — | +7.1% | +5.4% | +2.7% | +4.2% | +10.9% | +10.1% | +14.8% | +10.8% | +6.4% | +21.3% | +17.8% | +18.9% | +23.4% | +10.1% | +11.4% | +6.0% |
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Medical-Surgical Solutions | $2.64B | $2.95B | $2.95B | $2.85B | $2.70B | $2.95B | $2.99B | $2.87B |
| Prescription Technology Solutions | $1.24B | $1.27B | $1.37B | — | $1.43B | $1.38B | $1.50B | $1.50B |
| Corporate | — | $3.00M | $4.00M | — | — | — | — | — |
| International | $3.69B | $3.71B | $3.86B | $3.46B | $3.74B | — | — | — |
| North American Pharmaceutical | — | — | — | — | — | $86.48B | $88.32B | — |
| Oncology & Multispecialty | — | — | — | — | — | $12.04B | $13.01B | — |
| U.S. Pharmaceutical | $71.72B | $85.73B | $87.11B | $83.17B | $89.95B | — | — | — |
| Total | $79.28B | $93.65B | $95.29B | $90.82B | $97.83B | $103.15B | $106.16B | $96.30B |
Corporate, International, U.S. Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Total Revenue at Other Companies
Frequently Asked Questions
- What is McKesson's total revenue?
- McKesson (MCK) reported total revenue of $96.30B in Q1 2026.
- How has McKesson's total revenue changed year-over-year?
- McKesson's total revenue increased by 6.0% year-over-year, from $90.82B to $96.30B.
- What is the long-term trend for McKesson's total revenue?
- Over 4 years (2022 to 2026), McKesson's total revenue has grown at a 11.2% compound annual growth rate (CAGR), from $263.97B to $403.43B.
- What does total revenue mean?
- The total amount of money a company brings in from its primary business activities before any expenses.